Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat

Mineral and Electrolyte Metabolism

Volumn 24, Issue 6, 1998, Pages 406-411

  Anderson, Sharon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Albuminuria; Angiotensin; Angiotensin converting enzyme; Diabetes; Renin

Indexed keywords

ANGIOTENSIN; MESSENGER RNA; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL DAMAGE; DIABETIC NEPHROPATHY; HORMONE ACTION; HORMONE METABOLISM; HYPERGLYCEMIA; KIDNEY CELL; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM ABSORPTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HEMODYNAMIC PROCESSES; KIDNEY; KIDNEY GLOMERULUS; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0032443625     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057402     Document Type: Review

References (45)

1. Hostetter TH, Troy JL, Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-415.
2. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1988;77:1925-1930.
3. Anderson S: Antihypertensive therapy in experimental diabetes. J Am Soc Nephrol 1992;3:S86-S96.
4. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G: Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 1994; 5:1139-1146.
5. Anderson S, Jung FF, Ingelfinger JR: Reninangiotensin system in diabetic rats: Functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 1993;265:F477-F486.
6. Remuzzi A, Fassi A, Sangalli F, Malanchini B, Remuzzi G: Effect of benazapril and valsartan on glomerular injury in experimental diabetes in MWF/Ztm rats (abstract). J Am Soc Nephrol 1996;7:1877.
7. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani C, Remuzzi G: Short-and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4:40-49.
8. Okamoto K, Kashihara N, Sugiyama H, Sekikawa T, Maeshima Y, Kanao K, Sato M, Maruyama K, Makino H, Sugaya T, Hisada Y, Murakami K: Suppression of glomerular and renal hypertrophy in diabetes induced in angiotensin II type la receptor-deficient mice (abstract). J Am Soc Nephrol 1996;6:1876.
9. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993;118:129-138.
10. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 1995;10(suppl 9):39-45.
11. Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-87.
12. Viberti G, Mogensen CE, Group LC, Pauls JF, for the European Microalbuminuria Captopril Study Group: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279.
13. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329: 1456-1462.
14. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM-associated nephropathy. Kidney Int 1996;50:1641-1650.
15. American Diabetes Association. Position Statement: Diabetic Nephropathy. Diabetes Care 1998;21(supp 1):50-53.
16. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
17. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M: Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994;45(suppl 45):161-164.
18. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short and long term effects of antihypertcnsive therapy in the diabetic rat. Kidney Int 1989;36:526-536.
19. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-867.
20. Vora JP, Oyama TT, Thompson MM, Anderson S: Interactions of the kallikrein-kinin and reninangiotensin systems in experimental diabetes. Diabetes 1997;46:107-112.
21. Kennefick TM, Oyama TT, Thompson MM, Anderson S: Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol 1996;271:F595-F602.
22. Vallon V, Mead LM, Blantz RC: Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: Effects of sodium and salt restriction. J Am Soc Nephrol 1995;5:1761-1767.
23. Baylis C, Engels K, Hymel A, Navar EG: Age-dependent alterations in the metabolic clearance rate of angiotensin II in the rat (abstract). J Am Soc Nephrol 1995;6:731.
24. Gross V, Lippoldt A, Bohlender J, Ganten D, Ganten U, Luft FC: The renin-angiotensin system and renal function in transgenic (mRen2)27 rats. Exp Nephrol 1996;4(suppl 1):20-26.
25. Vernace MA, Herbert E, Mento PF, Maita ME, Wilkes BM: Increased metabolic clearance of angiotensin II in diabetic rats: Role of the kidneys (abstract). J Am Soc Nephrol 1994;5: 974.
26. Thaiss F, Wolf G, Assad N: Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats. Diabetologia 1996; 39:275-280.
27. Hsueh WA, Anderson PW: Prorenin and the renin-angiotensin system in diabetic nephropathy. Semin Nephrol 1993;13:573-580.
28. Harris RC, Cheng H-F: The intrarenal renin-angiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 1996;4(suppl 1): 2-7.
29. Seikaly MG, Arant BS Jr, Seney DF Jr: Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990;86:1352-1357.
30. 2 in rats with streptozotocin-induced diabetes. Naunyn Schmiedebergs Arch Pharmacol 1983;322:290-294.
31. Jost-Vu E, Horton R, Antonipillai I: Altered regulation of renin secretion by insulin-like growth factors and angiotensin II in diabetic rats. Diabetes 1992;41:1100-1105.
32. Everelt AD, Scott J, Wilfong N, Marino B, Rozenkranz RP, Inagami T, Gomez AR: Renin and angiotensinogen expression during evolution of diabetes. Hypertension 1992;19:70-78.
33. Correa-Rotter R, Hostetter TH, Rosenberg ME: Renin and angiotensinogen gene expression in experimental diabetes mellitus. Kidney Int 1992;41:796-804.
34. Jaffa AA, Chai KX, Chao J, Chao L, Mayfield RK: Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 1992;41:789-795.
35. Kalinyak JE, Sechi LA, Griffin CA, Don BR, Tavangar K, Kraemer FB, Hoffman AR, Schambclan M: The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 1993;4:1337-1345.
36. Cheng H-F, Burns KD, Harris RC: Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 1994;46:1603-1610.
37. Choi KC, Nim NH, An MR, Kang DG, Kim SW, Lee J-U: Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int 1997; 52(suppl 60):23-27.
38. Mizuiri S, Yoshikawa H, Tanagashima M, Mivagi M, Kobayashi M, Sakai K, Hayashi I, Aikawa A, Ohara T, Hasegawa A: Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998;31:301-307.
39. Cheng H-F, Becker BN, Burns KD, Harris RC: Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 1995;95:2012-2019.
40. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentjin AJ: Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991;18:763-773.
41. Price D, Porter L, De Oliveira J, Fisher N, Gordon M, Laffel L, Williams G, Hollenberg N: The paradox of the low-renin state: Hormonal and renal responses to an angiotensin II antagonist, irbesartan, in diabetic nephropathy (abstract). J Am Soc Nephrol 1996;7:1363.
42. Hsueh WA: Effect of the renin-angiotensin system in the vascular disease of type II diabetes mellitus. Am J Med 1992;92(suppl 4B):13-19.
43. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997;29:153-163.
44. Abboud HE: Growth factors and diabetic nephropathy: An overview. Kidney Int 1997; 52(suppl 60):3-6.
45. Hutchison FN, Cui X, Paul RV, Olivero M, Coffman TM: Increase in renal transforming growth factor β in diabetes is angiotensin II dependent (abstract). J Ann Soc Nephrol 1996; 7:1872.